Aptamers as immune checkpoint inhibitors in cancer immunotherapy: targeting CTLA-4/B7 and PD-1/PD-L1 pathways
International Immunopharmacology · 2025-10 · 164 · 115339
DOI: 10.1016/j.intimp.2025.115339 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025-10. Verfasst von Darshini Anantha Rajah und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Science, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Subang Jaya, Selangor Darul Ehsan 47500, Malaysia. Hauptthemen laut MEDLINE: Neoplasms, Immune Checkpoint Inhibitors, CTLA-4 Antigen, Immunotherapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia.
Abstract (Originalsprache)
The increasing burden of cancer underscores the urgent need for more effective treatment strategies. Cancer immunotherapy is a revolutionary, novel approach that harnesses the immune system's natural anticancer response; however, its success is often limited by tumour immune evasion mechanisms. Given the central role of cytotoxic T-cells in anticancer immunity, efforts have been directed toward enhancing their activity. One key strategy involves targeting immune checkpoint receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and programmed death 1 (PD-1), which suppress T-cell function. The blockade of these receptors using immune checkpoint inhibitors (ICIs) effectively restores T-cell activity, with FDA-approved monoclonal antibody inhibitors currently in clinical use. However, their adverse effects and inherent limitations highlight the need for alternative approaches - one of which is aptamers. As oligonucleotides, aptamers have numerous advantages, including ease of production, increased stability, small size, non-immunogenicity, and potential for conjugation with multiple molecules. Despite challenges such as vulnerability to nuclease degradation and excessive renal filtration, modifications have been explored to improve their therapeutic potential. Bispecific aptamers present an improved approach, with novel modified bispecific aptamers showing notable potential. Despite promising preclinical results, there are still currently no aptamer-based ICIs approved for clinical use. Given current advancements, aptamers as ICIs hold great promise as a next-generation cancer immunotherapy, offering a more precise, effective, and potentially safer alternative to traditional ICIs. This review suggests a novel DBCO-modified bispecific aptamer that simultaneously targets CTLA-4 and PD-L1 with improved localisation to the tumour site, which exemplifies a next-generation strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Science, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Subang Jaya, Selangor Darul Ehsan 47500, Malaysia.
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Subang Jaya, Selangor Darul Ehsan 47500, Malaysia. Electronic address: Reyhaneh.Farghadani@monash.ed…
Förderung
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia
Zitieren
APA
Anantha Rajah, D., Tan, H. S., & Farghadani, R. (2025). Aptamers as immune checkpoint inhibitors in cancer immunotherapy: targeting CTLA-4/B7 and PD-1/PD-L1 pathways. International Immunopharmacology, 164, 115339. https://doi.org/10.1016/j.intimp.2025.115339
Vancouver
Anantha Rajah D, Tan HS, Farghadani R. Aptamers as immune checkpoint inhibitors in cancer immunotherapy: targeting CTLA-4/B7 and PD-1/PD-L1 pathways. International Immunopharmacology. 2025;164:115339. doi:10.1016/j.intimp.2025.115339
BibTeX
@article{AnanthaRajah2025,
author = {Anantha Rajah, Darshini and Tan, Hock Siew and Farghadani, Reyhaneh},
title = {Aptamers as immune checkpoint inhibitors in cancer immunotherapy: targeting CTLA-4/B7 and PD-1/PD-L1 pathways},
journal = {International Immunopharmacology},
year = {2025},
volume = {164},
pages = {115339},
doi = {10.1016/j.intimp.2025.115339}
}
EUVIMED